In one paragraphArticle in The Journal of experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Shilpa SachanW. Harry Feinstone Department of Molecular Microbiology and Immunology, Lyme and Tickborne Diseases Research and Education Institute, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.ORCID 0009-0005-9809-4766 Giang Vu Vi TranCenter for Immunology and Infectious Diseases and Department of Pathology, Microbiology and Immunology, School of Veterinary Medicine, University of California, Davis, CA, USA.ORCID 0000-0003-0993-1672 Kimberly J OlsenCenter for Immunology and Infectious Diseases and Department of Pathology, Microbiology and Immunology, School of Veterinary Medicine, University of California, Davis, CA, USA.ORCID 0009-0005-8085-3576 Heather KulagaW. Harry Feinstone Department of Molecular Microbiology and Immunology, Lyme and Tickborne Diseases Research and Education Institute, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.ORCID 0009-0003-5110-8361 Anne DayW. Harry Feinstone Department of Molecular Microbiology and Immunology, Lyme and Tickborne Diseases Research and Education Institute, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.ORCID 0009-0008-1330-3138 Hannah P SavageDepartment of Microbiology and Immunology, School of Medicine, University of California, Davis, CA, USA.ORCID 0000-0002-1057-7239 Alison W RebmanLyme Disease Research Center, Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0001-7240-7158 John N AucottLyme Disease Research Center, Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-2648-0896 Isabel A JimenezW. Harry Feinstone Department of Molecular Microbiology and Immunology, Lyme and Tickborne Diseases Research and Education Institute, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.ORCID 0000-0002-5384-7809 Cory F BraytonDepartment of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-6666-6548 Nicole BaumgarthW. Harry Feinstone Department of Molecular Microbiology and Immunology, Lyme and Tickborne Diseases Research and Education Institute, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.ORCID 0000-0002-2891-4483 Funding
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Anna Palmer Durbin · 2012 to 2026
$67.0MTraining Veterinarians for Careers in Biomedical ResearchT32OD011089 · OD · JOHNS HOPKINS UNIVERSITY · PI JOSEPH L MANKOWSKI · 2012 to 2026
$6.7MAntibody-mediated immunity to Borrelia burgdorferiR01AI157007 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BAUMGARTH, NICOLE · 2021 to 2025
$2.4MTraining Veterinary Students for Careers in Biomedical ResearchT35OD024982 · OD · JOHNS HOPKINS UNIVERSITY · PI MANKOWSKI, JOSEPH L · 2019 to 2024
$226kDevelopment of Faux-Biotics to combat the spread of hospital-acquired antibiotic-resistant infectionsF32AI161850 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI SAVAGE, HANNAH P · 2021 to 2022
$136kBay Area Lyme FoundationCongressionally Directed Medical Research Programs TB220074Global Lyme AllianceNational Institute of Allergy and Infectious DiseasesNational Institutes of Health/National Institute of Allergy and Infectious Diseases 5T35 OD024982National Institutes of Health/National Institute of Allergy and Infectious Diseases F32AI161850National Institutes of Health/National Institute of Allergy and Infectious Diseases R01 AI157007National Institutes of Health/National Institute of Allergy and Infectious Diseases T32OD011089NIAID NIH HHS F32 AI161850NIAID NIH HHS P30 AI094189NIAID NIH HHS R01 AI157007NIH HHS T32 OD011089NIH HHS T35 OD024982Steven and Alexandra Cohen Foundation
6 · The paper itselfAbstract
Lyme disease, an emerging tickborne disease caused by Borrelia burgdorferi (Bb), can result in myriad symptoms of unknown causes in humans. Here, we show that Bb rapidly disrupts the gastrointestinal immune barrier in infected mice, inducing a "leaky gut" syndrome, characterized by increased gut permeability, systemic endotoxemia, elevated LPS binding protein and intestinal fatty acid binding protein, and altered blood leukocyte profiles. Patients with acute Lyme disease showed similar blood changes that correlated with disease symptoms and liver function measurements and largely resolved after antibiotic treatment. Mechanistically, Bb infection triggered mild early inflammation in the small intestine and suppressed humoral immunity to the microbiota, resulting in reduced IgA coating of fecal microbes and decreased antimicrobial serum IgG, despite the increased gut permeability. These defects preceded shifts in later observed gut bacterial composition and short-chain fatty acid production. Together, our findings identify mucosal barrier dysfunction and impaired antimicrobial humoral immunity as potential drivers of Bb-induced disease.
Indexed as
Antibodies, BacterialBorrelia burgdorferiGastrointestinal MicrobiomeLyme DiseaseAnimalsFemaleHumansImmunity, HumoralImmunoglobulin AImmunoglobulin GIntestinal Barrier FunctionIntestinal MucosaMaleMiceMice, Inbred C57BLAntibodies, BacterialImmunoglobulin AImmunoglobulin G
Identifiers
PMID42635742
PMCPMC13502156
What OpenQuestion holds
Textmetadata
Read underepoch 390